EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reprogramming M2 macrophages via TLR7/8 agonist-loaded hollow MnO2 nanovehicles to suppress the progression of liver cancer

Pei-Pei He iD, Zheng-Ju Hou, Han-Mei Li, Ji-Xuan Zhang, An-Qi Chen, Quan-You Miao, Chao-Feng Yang, Jin-Hong Yu, Yang Li

PLOS One · 2026

DOI: 10.1371/journal.pone.0358567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Pei-Pei He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China. Hauptthemen laut MEDLINE: Oxides, Manganese Compounds, Imidazoles, Nanoparticles. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanchong City School Science and Technology Strategic Cooperation Project, Research and Development Program of North Sichuan Medical College, Guang’an Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a prevalent malignancy, liver cancer ranks as the third most common cause of cancer mortality globally. Within the tumor microenvironment, tumor-associated macrophages (TAMs) exhibit contrasting functional phenotypes: the anti-tumor M1 type and the pro-tumor M2 type. Reprogramming TAMs from the M2 to the M1 phenotype has emerged as a promising immunotherapeutic strategy. Here, we engineered a multi-nano therapeutic system, PAH@HMMDN@R848, by loading a TLR7/8 agonist (R848) onto hollow MnO 2 nanoparticles (HMMDN) and coating with polyallylamine hydrochloride (PAH). In vitro, this system efficiently repolarized M2 macrophages to the M1 phenotype, evidenced by decreased CD206, Arg-1, IL-10 and increased CD80, iNOS, TNF-α (P < 0.05). Under acidic/glutathione-rich conditions, HMMDN degraded to release Mn 2+ , which served as a T 1 -weighted MRI contrast agent with a high relaxivity (r 1 = 5.255 mM - 1 s - 1 ). Mechanistically, PAH@HMMDN@R848 activated both NF-κB (via R848) and STING (via Mn 2+ ) pathways, leading to synergistic M1 polarization. In a subcutaneous H22 liver cancer mouse model, intratumoral injection of PAH@HMMDN@R848 significantly suppressed tumor growth (tumor inhibition rate 80.6%) without obvious systemic toxicity. Immunohistochemistry and cytokine analysis revealed that the treatment increased M1 macrophage infiltration (CD80 + ) and reduced M2 macrophages (CD206 + ) within tumors, along with elevated TNF-α/iNOS and decreased IL-10/Arg-1. This study presents a multifunctional nanoplatform capable of TAMs reprogramming and MRI diagnosis, offering a promising approach for liver cancer theranostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxidesManganese CompoundsImidazolesNanoparticlesToll-Like Receptor 7Toll-Like Receptor 8Liver NeoplasmsMacrophagesAnimalsMiceToll-Like Receptor AgonistsCell Line, TumorPolyaminesDisease ProgressionHumansTumor MicroenvironmentMembrane Glycoproteins

Substanzen

OxidesManganese CompoundsToll-Like Receptor AgonistsImidazolesToll-Like Receptor 7Toll-Like Receptor 8resiquimodmanganese dioxidepolyallylaminePolyamines

Autor:innen und Institutionen

  • Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
  • Innovation Centre for Science and Technology of North Sichuan Medical College, Nanchong, Sichuan, China.
  • Biotechnology Innovation Drug Application and Transformation Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong, Sichuan Province, China.
  • Department of Ultrasound, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

ORCID-Profile: Pei-Pei He

Förderung

  • Nanchong City School Science and Technology Strategic Cooperation Project
  • Research and Development Program of North Sichuan Medical College
  • Guang’an Science and Technology Bureau

Zitieren

APA

He, P. P., Hou, Z. J., Li, H. M., Zhang, J. X., Chen, A. Q., Miao, Q. Y., Yang, C. F., Yu, J. H., & Li, Y. (2026). Reprogramming M2 macrophages via TLR7/8 agonist-loaded hollow MnO2 nanovehicles to suppress the progression of liver cancer. PLOS One. https://doi.org/10.1371/journal.pone.0358567

Vancouver

He PP, Hou ZJ, Li HM, Zhang JX, Chen AQ, Miao QY, et al. Reprogramming M2 macrophages via TLR7/8 agonist-loaded hollow MnO2 nanovehicles to suppress the progression of liver cancer. PLOS One. 2026. doi:10.1371/journal.pone.0358567

BibTeX
@article{He2026,
  author = {He, Pei-Pei and Hou, Zheng-Ju and Li, Han-Mei and Zhang, Ji-Xuan and Chen, An-Qi and Miao, Quan-You and Yang, Chao-Feng and Yu, Jin-Hong and Li, Yang},
  title = {Reprogramming M2 macrophages via TLR7/8 agonist-loaded hollow MnO2 nanovehicles to suppress the progression of liver cancer},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0358567}
}
Kostenlos starten →